<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164728">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01798797</url>
  </required_header>
  <id_info>
    <org_study_id>TRIAGE-HF</org_study_id>
    <nct_id>NCT01798797</nct_id>
  </id_info>
  <brief_title>Integrated Diagnostic for Heart Failure</brief_title>
  <acronym>no</acronym>
  <official_title>Integrated Diagnostic for Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective post-market study to evaluate the performance and clinic usability of heart
      failure risk status (HFRS) feature on CareLink.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with systolic heart failure (HF) implanted with Medtronic wireless implantable
      cardiac defibrillator (ICD) or cardiac resynchronization therapy device with defibrillation
      capabilities (CRT-D) devices will be enrolled in the study. The purpose of the study is to
      evaluate the usability of CareLink HFRS to manage a patient's heart failure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Heart Failure Risk Status Performance Characterization</measure>
    <time_frame>from baseline until a subject completes 8 months of follow up</time_frame>
    <safety_issue>No</safety_issue>
    <description>The clinical signs and symptoms of worsening HF that are associated with an Heart Failure Risk Status triggered by an OptiVol alert</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart Failure Risk Status and medical management</measure>
    <time_frame>from baseline for each subject until they complete 8 months of follow up</time_frame>
    <safety_issue>No</safety_issue>
    <description>The correlation between HFRS burden and clinician's assessment of a subject risk and the subject's medical management</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>no treatment</arm_group_label>
    <description>non-randomized, all subjects who have been implanted with an ICD or CRT-D for at least 3 months</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with heart failure who have been implanted with an ICD or a CRT-D wirless device
        for at least 3 months
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is 18 years of age or older

          -  Patient ( or patient's legally authorized representative) is willing and able to
             provide written informed consent

          -  Patient is willing and able to comply with the required study follow up visits

          -  Patient is implanted with a Medtronic wireless ICD or CRT-D device capable of OptiVol
             fluid monitoring feature

          -  Patient is on Medtronic CareLink network or is willing to be enrolled on the CareLink
             network

          -  Patient is being managed, or has been managed, by a HF clinician

          -  Patient has signed an informed consent for CareLink Network Services

          -  Patient is implanted with device for at least three months

          -  Patient is willing and able to transmit data using the CareLink home monitor (2490C).

        Exclusion Criteria:

          -  Patient is  participating in another study that may interfere with TRIAGE-HF protocol
             required procedures

          -  Patient with an implantable cardiac device that is indicated to  reach ERI in less
             than 12 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean Virani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vancouver General Hospital, Vancouver, British Columbia, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean Virani, MD</last_name>
      <phone>604-875-5092</phone>
    </contact>
    <contact_backup>
      <last_name>Naomi Uchida, RN</last_name>
      <phone>604-975-4521</phone>
    </contact_backup>
    <investigator>
      <last_name>Sean Viani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Bennett, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Boniface Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelley Zieroth, MD</last_name>
      <phone>204-237-2744</phone>
    </contact>
    <contact_backup>
      <last_name>Angie Munoz, RN</last_name>
      <phone>204-237-2793</phone>
    </contact_backup>
    <investigator>
      <last_name>Shelley Zieroth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 3, 2013</lastchanged_date>
  <firstreceived_date>February 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>HFRS</keyword>
  <keyword>OptiVol</keyword>
  <keyword>ICD</keyword>
  <keyword>CRT-D</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
